Key facts
- This page summarizes Robert Renninger's Form 4 filing for Athira Pharma, Inc. (ATHA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Oct 2024, 19:17.
Robert Renninger - 01 Oct 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)
- Reporting relationship
- VP of Finance
- Issuer ticker
- ATHA
- Reported as of
- 01 Oct 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Oct 2024, 19:17:34 UTC
- Next SEC filing
- 03 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- s/ Mark Worthington, Attorney-in-Fact for Robert Renninger
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert Renninger filed Form 4 for Athira Pharma, Inc. (ATHA) on 03 Oct 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATHA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +37,077
- Change %
- Price
- $0.000000
- Shares after
- 37,077
- Date
- 01 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,077
- Exercise price
- Footnotes
- F1, F2
ATHA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +37,077
- Change %
- Price
- $0.000000
- Shares after
- 37,077
- Date
- 01 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,077
- Exercise price
- $0.4499
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
Footnote F2
One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.
Footnote F3
One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates.